Using an immunoassay as an initial screening tool saved approximately $36,000 over multiplex PCR panel use alone when performed in a period of high flu prevalence.
Qiagen believes the flexibility of the Stat-Dx platform for an evolving reimbursement landscape will set it apart from other similar commercial platforms.
Researchers found that 98 percent of the identifications the system provided were correct, indicating the usefulness of the platform in clinical mycology.
Areas like pharma and food and water testing could prove growth areas for the platform as instrument sales growth slows in the clinic microbiology space.
